FDA speeds up approval for new over-the-counter drugs.
H.R. 9774 — To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes. · Filed by Robert Latta (R-OH) · 1 cosponsor · Introduced Jul 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill lets drug makers ask the FDA to fast-track new over-the-counter drugs. The FDA must decide within 60 days if a drug gets priority status. Priority drugs still must pass all safety tests. The FDA reviews them faster with a dedicated project lead. The FDA must list health problems where over-the-counter drugs could help. The program ends in 2032.
Who it affects
People who buy over-the-counter drugs may get new treatments faster. Drug makers can bring new over-the-counter products to stores more quickly.
One thing to notice
The bill speeds up review but does not change safety tests.
From the analysis of the bill text, linked under Primary records below.
Where it stands
1 cosponsor: 1 Democrats.
- Jul 20, 2026 — Introduced · Congress.gov: “Introduced in House”
- Jul 20, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 groups reported lobbying about this bill. They filed 1 reports from Sep 2026 to Sep 2026.
Those reports show $180,000 in lobbying spending. Each report lists about 3 bills. So that money was not all for this bill.
More groups named this bill than 0% of bills with any report.
Robert Latta, who sponsored the bill, received $953,126 from PACs for the 2026 election.
- Chattem, Inc D/b/a Opella — $180,000 in 1 report
Lobbying is legal. These reports show who lobbied about this bill, not what changed.
Words to know
- over-the-counter drugs — Medicines people can buy without a doctor's prescription.
- priority status — A label that tells the FDA to review a drug faster.
- project lead — A person at the FDA who guides the drug review process.
- lobbying — Trying to influence lawmakers about a bill. Companies and groups pay people to do this.
- PACs — Groups that collect money and give it to candidates for office.
- sponsored — To sponsor a bill is to introduce it in Congress and put your name on it.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,803 characters) on Aug 12, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Sep 2026 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 6, 2026 · page rendered 2026-11-22.
“FDA speeds up approval for new over-the-counter drugs.” QuorumCivic. https://share.quorumcivic.app/bill/119/hr9774/simple Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.